Samsung Bioepis settlement with J&J for Pyzchiva in Europe
South Korea’s Samsung Bioepis. has signed a settlement and license agreement with Johnson & Johnson (NYSE: JNJ) concerning the commercialization of Pyzchiva, a biosimilar to J&J’s Stelara (ustekinumab), in Europe. The terms of the agreement remain confidential.
Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of interleukin (IL)-12 and IL-23 associated with immune-mediated diseases. Pyzchiva, developed by Samsung Bioepis, was approved as a biosimilar to Stelara by the European Commission (EC) in April 2024. Pyzchiva is currently approved for the treatment of adults and pediatric patients from the age of six years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease.
Launched by Sandoz
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze